Investing.com - Financial Markets Worldwide

CHA Vaccine Research Institute (261780)

KOSDAQ
Currency in KRW
2,910
+20(+0.69%)
Delayed Data·

261780 Financial Summary

Key Ratios

P/E Ratio-7.35
Price/Book3.3
Debt / Equity40.12%
Return on Equity-38.17%
Dividend Yield0.00%
EBITDA-7.21B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa179.48294.12370.66
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa160.49259.62346.73
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-6,469.26-6,419.35-7,696.42
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-6,715.16-1,749.5-10,138.37
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa61,068.7945,119.1147,248
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa26,789.22810.189,613.45
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa33,365.635,416.9527,722.31
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-6,798.81-10,251.17-2,182.53
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-5,188.56-5,293.25-8,095.6
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa3,736.4221,929.732,291.35
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-116.29-13,116.679,990.26
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-1,568.433,519.84,186
* In Millions of KRW (except for per share items)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-96.00 / --
Revenue / Forecast
-- / --
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What was CHA Vaccine Research Institute's net income for the latest quarter?

CHA Vaccine Research Institute's net income for the latest quarter was -2,573.90.

What is CHA Vaccine Research Institute's net profit margin on a TTM basis?

CHA Vaccine Research Institute's trailing twelve months (TTM) net profit margin is -2,735.23%.

How does CHA Vaccine Research Institute's debt to equity ratio compare to industry standards?

CHA Vaccine Research Institute's total debt-to-equity ratio is 40.12%.

What is CHA Vaccine Research Institute's return on investment on a TTM basis?

CHA Vaccine Research Institute's trailing twelve months (TTM) return on investment (ROI) is -38.17%.

Did CHA Vaccine Research Institute gain or lose cash last quarter?

In the latest quarter, CHA Vaccine Research Institute's net change in cash was -7,978.73 million.

What were CHA Vaccine Research Institute's total assets and liabilities in the latest quarter?

As of the latest quarter, CHA Vaccine Research Institute reported total assets of 45,199.20 million and total liabilities of 9,885.04 million.

What is CHA Vaccine Research Institute's gross margin on a TTM basis?

CHA Vaccine Research Institute's trailing twelve months (TTM) gross margin is 100.00%.

What was CHA Vaccine Research Institute's revenue per share for the latest quarter?

CHA Vaccine Research Institute's revenue per share for the latest quarter was 1,038.75.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.